Government ContextGovernment Context
ActivityRulesGrantsPress releasesHearingsBills
ViewsAgenciesTopicsOrganizationsCommitteesLegislators
PricingLog inCreate account
Nonrulemaking

Request that the FDA grant permission to file an abbreviated new animal drug application (ANADA) for a generic soft chewable tablet for Graphiprant that differs from the pioneer product Galliprant (grapiprant tablets), sponsored by Elanco US Inc, under NADA 141-455

🏛 Food and Drug Administration (FDA)FDA-2026-P-5875
Animal Health & Welfare
Documents
5
Total comments
0
all analyzed
Comment status
Open
Last activity
—
In this docket

Documents

Rules, notices, and supporting material — the primary rule pinned first.

All 5Other 3Supporting & Related Material 2
📄 Primary document
OtherJun 16, 2026
Amendment to Suitability Petition from Felix Pharmaceuticals Pvt. Ltd.
No comment period
Open →